The higher dosage was shown to help the average patient lose 21% of their body weight ...

Semaglutide, the active ingredient in the anti-obesity drug Wegovy, offers cardiovascular benefits for patients without diabetes who have established heart disease, but price reductions would be ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent ...

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding. Levin also explores the broader outlook for oral ...

By Rishika Sadam and Sriparna Roy HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories hopes to launch a ...

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

The oral version of Wegovy has made GLP-1 medicines more accessible and acceptable to many patients who had steered clear of injectable versions, healthcare analytics firm Truveta suggests.

Feb 11 (Reuters) - Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials. "We are exploring ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.

A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. | A ...